Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease (REMIND)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ortho-McNeil Neurologics, Inc.
ClinicalTrials.gov Identifier:
NCT00283725
First received: January 27, 2006
Last updated: January 24, 2013
Last verified: January 2013

January 27, 2006
January 24, 2013
June 2003
December 2006   (final data collection date for primary outcome measure)
Change from baseline in Mini Mental State Examination (MMSE) scale score at Month 24 [ Time Frame: Baseline, Month 24 ] [ Designated as safety issue: No ]
MMSE is a brief 30-point questionnaire test that is used for the assessment of dementia patients' cognitive impairment. Evaluation of points are as: 24-30 = No cognitive impairment, 18-23 = Mild cognitive impairment, 0-17 = Severe cognitive impairment. Lower scores indicate worsening.
Not Provided
Complete list of historical versions of study NCT00283725 on ClinicalTrials.gov Archive Site
  • Change from baseline in clinical global impression (CGI) scale score at Month 24 [ Time Frame: Baseline, Month 24 ] [ Designated as safety issue: No ]
    The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients". Higher scores indicate worsening.
  • Change from baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) at Month 24 [ Time Frame: Baseline, Month 24 ] [ Designated as safety issue: No ]
    The NPI is a validated clinical instrument for evaluating psychopathology in dementia to quantify and qualitate changes in psychiatric symptoms. It has 13-point scale and each is rated as follows: 1= mild (noticeable, but not a significant change), 2= moderate (significant, but not a dramatic change), and 3= Severe (very marked and prominent: a dramatic change). Higher scores indicate worsening.
  • Change from baseline in Zarit caregiver burden scale score at Month 24 [ Time Frame: Baseline, Month 24 ] [ Designated as safety issue: No ]
    Zarit caregiver burden scale is used to measure caregiver burden as it relates to time, developmental comparison with peers, physical health, social relationships, and emotional health. It has 22 item and each question is scored on a 5-point Likert scale ranging from 0 = never present to 4 = nearly always present. The sum of the total scores of the 22-items is calculated in the range from 0 (low burden) to 88 (high burden). Higher scores indicate worsening.
  • Change from baseline in Kaplan-Meier estimate at Month 24 [ Time Frame: Baseline, Month 24 ] [ Designated as safety issue: No ]
    By using Kaplan-Meier Estimator, the effect of an intervention is assessed by measuring the number of patients survived or saved after that intervention is given over a period of time. At any time point, the survival will be measured by the following formula: Number of patients living at the start minus Number of patients died divided by Number of patients living at the start.
  • Number of patients with adverse events [ Time Frame: Up to 24 months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
Review of Management Strategies in Dementia

The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal caregivers.

This is a 2-year, multicenter, prospective (look forward using periodic observations collected predominantly following patient enrollment), longitudinal (it is a co relational research study that involves repeated observations of the same variables over long periods of time), and observational study. The objective of this study is to examine the patients with mild and moderate AD who are currently being treated with different treatment care methods in real-world settings. Doctors will not be provided medication or asked to treat their patients with any particular treatment. The effect of the different management strategies on cognition, activities of daily living, and behavior of the patients will be evaluated, and data on the informal caregiver burden will be assessed. Data on the utilization of health and social care services by the patient and the primary informal caregiver, including admission of the patient to an assisted living facility or nursing home will be assessed. The doctor's assessment of clinical global impression and adverse events will also be documented. Data will be collected from the doctors at baseline and at 6, 12, and 24 months, and from the caregivers at baseline and 6, 12, 18, and 24 months. The medication dosage and administration is based upon the doctors' prescription, individualized for the patient and not dictated by the protocol.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with demetia with mild to moderate Alzheimer's disease.

  • Dementia
  • Alzheimer's Disease
Other: No intervention
Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
  • Galantamine
    Intervention: Other: No intervention
  • No Alzheimer's disease (AD) treatment
    Intervention: Other: No intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
573
December 2006
December 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a physician-based diagnosis of mild to moderate Alzheimer's disease (Mini-Mental State Examination [MMSE] score between 10-24)
  • Must be living at home or in a facility for the elderly (eg, assisted living), who live with or have frequent visits from a friend or relative (caregiver) or with a behavioral symptom (eg, as agitation or wandering)
  • Have no plan to change the current treatment plan for at least 90 days

Exclusion Criteria:

  • Have been using an acetylcholinesterase inhibitor or memantine currently but have used one in the past 30 days
  • Must be residing in or planning to move to a nursing home within the next 90 days or patients participating in another clinical trial
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00283725
CR004636, GALALZ4004, GAL-OUT-065
No
Ortho-McNeil Neurologics, Inc.
Ortho-McNeil Neurologics, Inc.
Not Provided
Study Director: Ortho-McNeil Neurologics, Inc. Clinical Trial Ortho-McNeil Neurologics, Inc.
Ortho-McNeil Neurologics, Inc.
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP